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Background: Diagnostic delay in common variable immunodeficiency disorders (CVID)
is considerable. There is no generally accepted symptom-recognition framework for its
early detection.
Objective: To systematically review all existing data on the clinical presentation of CVID.
Methods: PubMed, EMBASE and Cochrane were searched for cohort studies, published
January/1999-December/2019, detailing the clinical manifestations before, at and after
the CVID-diagnosis.
Results: In 51 studies (n=8521 patients) 134 presenting and 270 total clinical
manifestations were identified. Recurrent upper and/or lower respiratory infections were
present at diagnosis in 75%. Many patients had suffered severe bacterial infections
(osteomyelitis 4%, meningitis 6%, septicemia 8%, mastoiditis 8%). Bronchiectasis (28%),
lymphadenopathy (27%), splenomegaly (13%), inflammatory bowel disease (11%),
autoimmune cytopenia (10%) and idiopathic thrombocytopenia (6%) were also
frequently reported. A bimodal sex distribution was found, with male predominance in
children (62%) and female predominance in adults (58%). 25% of CVID-patients
developed other manifestations besides infections in childhood, this percentage was
much higher in adults (62%). Immune-dysregulation features, such as granulomatous-
lymphocytic interstitial lung disease and inflammatory bowel disease, were more
prominent in adults.
Conclusions: The shift from male predominance in childhood to female predominance
in adults suggests differences in genetic and environmental etiology in CVID and has
consequences for pathophysiologic studies. We confirm the high frequency of
respiratory infections at presentation, but also show a high incidence of severe
bacterial infections such as sepsis and meningitis, and immune dysregulation features
including lymphoproliferative, gastrointestinal and autoimmune manifestations. Early
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detection of CVID may be improved by screening for antibody deficiency in patients with
these manifestations.
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INTRODUCTION
Common variable immunodeficiency disorders (CVID) is a
collection of heterogeneous clinical manifestations linked by
low serum levels of immunoglobulins and primary failure of
specific antibody production (1–3). The rates of serious
comorbidities and resulting mortality of patients with CVID
drastically exceed the respective rates in the general population,
imposing a high disease burden to the individual patient (4, 5).
Although CVID is the most common symptomatic primary
immunodeficiency (PID), it is still a rare disease with a greatly
varying observed prevalence between countries, ranging in
“industrialized countries” from 6.9/100,000 in Finland to 0.6/
100,000 in Spain (6–14) and even lower observed prevalence
rates (<0.5/100,000) in “developing” countries (15). Therefore,
CVID has a low prevalence in primary care and general hospital
settings, where non-immunologists have little knowledge of this
disease. Also, respiratory infections and non-infectious
complications of CVID such as lymphoproliferation,
granulomatous disease and autoimmunity are much more
prevalent without concomitant CVID. This makes it
challenging to front-line clinicians to recognize CVID in these
cases. Because of the variability of presenting clinical
manifestations, patients visit various physicians of different
specialties in search of a diagnosis, which increases the risk of
missing the overarching clinical pattern and thereby overlooking
the underlying hypogammaglobulinemia (16).
Timely diagnosis and optimal management are likely to result
in improved clinical and quality-of-life outcomes for patients
with CVID, higher participation in society (school, work) and
lower health care costs (4, 17–19). Reducing diagnostic delay is
therefore crucial; current approaches mainly comprise
improving education and awareness of clinicians in both
primary and secondary care. Already a long time ago, the
Jeffrey Modell Foundation (JMF) developed ten (mainly
p e d i a t r i c ) ( 2 0 ) a n d t h e E u r o p e a n S o c i e t y f o r
Immunodeficiencies (ESID) six (adult) ‘Warnings Signs’ to
indicate PIDs (21). Unfortunately, these signs have turned out
to have a low sensitivity for timely PID diagnosis (22, 23).
In order to improve our insight in the early presentation of
CVID and to assist physicians in its timely detection, we aimed to
systematically identify and collate existing published cohort
studies on the presenting clinical manifestations at and before
diagnosis. In addition, we included the overall clinical
manifestations during disease follow-up in our systematic
review; this was done separately for children and adults to




We searched EMBASE, Cochrane and PubMed from January
1999 to December 2019 (inclusive) using a combination
of subject headings and free text incorporating the
terms ‘common variable immunodeficiency’, ‘late onset
hypogammaglobulinemia’, and ‘diagnosis’, and limited to
English language and humans. Reference lists of included
studies were also searched for potentially relevant studies
(snowball method). The complete search strategy is detailed in
the supplementary appendix eSearch. The protocol of this
systematic review has been registered on PROSPERO with
registration number CRD42019121384.
Study Selection
We considered all primary research studies for selection, either
retrospective or prospective, of any study design (e.g., case series,
cohort), describing the clinical manifestations for a minimum of
10 patients with CVID. Two researchers (LJ and EV)
independently screened titles and abstracts of all papers,
excluding clearly irrelevant studies. Hereafter, they
independently reviewed the full text of remaining papers to
assess eligibility. If multiple updates of a cohort were
published, the most recent study with the largest dataset
describing the total clinical picture of their CVID cohort was
included, in order to avoid duplicates of patients in our review.
The large European multicenter study by Gathmann et al. (24)
was excluded for analysis to avoid overlapping data, because this
study collated data from multiple centers that already published
a substantial amount of their data as single-center cohorts in
more detail. Three European multicenter studies (25–27)
partially overlapped in their included centers; in this case the
largest multicenter study by Chapel et al. describing the overall
clinical picture of CVID was included (26) (for details about the
handling of overlapping data, see Supplementary Table 1).
Studies that selected cases based on the presence of only
certain clinical features of CVID (e.g., only granulomatous,
pulmonary, gastrointestinal or autoimmune manifestations)
were excluded to avoid giving disproportionate weight to those
features in the data synthesis, unless the total number of CVID
patients from which these cases were selected was also reported.
Abbreviations: CASP, critical appraisal skills program; CVID, common variable
immunodeficiency disorders; ESID, European Society of Immunodeficiency;
ICON, international consensus document; LOCID, late onset combined
immunodeficiency; MOOSE, meta-analysis of observational studies in
epidemiology; PID, primary immunodeficiency; SE, standard error; STROBE,
strengthening the reporting of observational studies in epidemiology.
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When the same center/registry published an article about their
total cohort and another article in which children and/or adults
were separately described, these children- and adult-specific
overlapping data were only included in the subgroup analysis
for children vs adults. Any uncertainties regarding study
selection were discussed between LJ, MF, and EV.
Quality Assessment
After assembling a shortlist of studies eligible for potential
inclusion, LJ assessed the risk of bias in these studies to ensure
that only those studies with an acceptable risk of bias were
included. This quality assessment was checked by EV. Because
there is no validated quality checklist for assessing retrospective
cohort studies, we constructed a checklist based on relevant items
from the MOOSE (meta-analysis of observational studies in
epidemiology) reporting guideline for observational studies
(28) , the STROBE (strengthening the reporting of
observational studies in epidemiology) reporting guideline for
cohort studies (29) and CASP (critical appraisal skills program)
guidelines for case-control and cohort studies (checklist in
Supplementary Table 2) (30). Quality was assessed as
‘acceptable’ or ‘unacceptable’ in three domains: definition of
CVID, selection of cases, and methods for extracting data on
included cases. ‘Acceptable’ for case definition required cases to
be defined according to the diagnostic criteria of ESID/Pan-
American Group for Immunodeficiency (PAGID) (3), the ESID
Registry working definitions for clinical diagnosis of PID (www.
esid.org), the International Union of Immunological Societies
(IUIS) criteria (31), the World Health Organization (WHO)
scientific group (32) or the international consensus document
(ICON) (33) (Supplementary Table 3), or - if no reference was
made to which diagnostic criteria were used - description of the
inclusion criteria corresponding to the above described
diagnostic criteria. Although we only included articles about
pediatric CVID that reported to have only included established
CVID patients, we cannot completely rule out that a few of these
patients actually had transient hypogammaglobulinemia of
infancy. ‘Acceptable’ for case selection required that at least
two of the participants’ baseline characteristics were clearly
documented and that the characteristics of cases were
sufficiently consistent with the current knowledge regarding
CVID (i.e., the age and sex distribution of cases matched the
known epidemiology of CVID). ‘Acceptable’ for data extraction
required the use of a standardized data collection format and/or
the objective measurement of signs (e.g., CT confirmation of
bronchiectasis, biopsy confirmation of granulomas).
Disagreements between the two reviewers (LJ and EV) were
discussed with a third reviewer (MF) until agreement was
achieved. Only studies considered by the two reviewers to be
acceptable for case definition and to pass in at least one other
domain were included, and data related to the ‘unacceptable’
domain were not included in this review.
Data Extraction
Data were extracted from included studies by LJ using a
standardized Microsoft Excel spread sheet and were checked
by EV and MF. We extracted study characteristics including year
of publication, country, recruitment periods, number and type of
centers, study design, number of patients, age and sex. Clinical
manifestations were recorded, and numbers of patients with each
manifestation were noted. This was done separately for the
clinical manifestations at presentation (at or before diagnosis)
and overall (at any timepoint). When this distinction was not
described, the manifestations were collected as ‘overall’ in the
standardized format. When a clinical manifestation was not
discussed in a study, we made no assumption about whether
or not that manifestation had occurred in that population but
recorded this item as ‘missing data’ for the respective study in the
standardized format. We deliberately chose to use the exact
wordings of the included studies, to avoid interpretation bias.
Clinical manifestations were never counted twice. For example,
where one study separately described sinusitis and otitis, another
study only mentioned ‘upper respiratory tract infections’. In
addition, we recorded whether in a cohort, children, adults or
both were described. A pediatric cohort was defined as age
during follow-up <18 years old, which was comparable to the
cut-off value for children’s age provided by the original studies.
We did not contact the authors of included papers to collect
additional information.
Statistical Analysis
We used MetaXL (version 5.3, EpiGear International,
Queensland, Australia) to calculate proportions and standard
errors (SEs) of proportions for each clinical manifestation in each
included study (34). To combine the results of multiple cohorts,
we calculated pooled proportions of each clinical manifestation
using the metan command. Anticipating high heterogeneity
between included studies, we performed random effects meta-
analysis using the DerSimonian and Laird method and standard
methods to calculate I2 as an estimate of heterogeneity. In
addition, we conducted two subgroup analyses using the same
techniques: 1) children vs adults, and 2) clinical manifestations at
presentation vs overall clinical manifestations during the disease
course. A subgroup analysis based on age was conducted because
the few available studies on differences between pediatric-onset
and adult-onset CVID have yielded limited and conflicting data
(35–37). In order to improve our understanding of the early
presentation of CVID, which can assist clinicians in timely
detection of this condition, we focused our analysis on clinical
manifestations at or prior to diagnosis.
RESULTS
Search Results
After removal of duplicates, we identified 1604 papers. We
excluded 1453 after screening titles and abstracts, and a further
96 after full-text assessment (Figure 1), based on the inclusion
criteria (see Method). Reference lists of included studies yielded
21 additional eligible studies. There was full consensus between
the authors regarding study inclusion.
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Characteristics of Included Studies
The 51 included studies described clinical manifestations in a
total of 8521 patients (Table 1) (5, 6, 19, 26, 35–81). 50 studies
were conducted in one or more centers in one country only, in 18
different countries in total; 1 study included multiple centers
from different countries (26). Most were cohort studies (5
prospective, 42 retrospective) and three compared cases with
controls. All 51 studies extracted data from written/typed
hospital records. The majority of studies (n=39) identified
cases from hospital records alone; others also used regional,
national, or continental registries of primary immunodeficiencies
(n=12). Three studies also obtained data from a patient and/or
parent-completed questionnaire (41, 45, 55). Fifteen studies
reported clinical manifestations of their total CVID cohort, but
reported in more detail on patients based on the presence of only
certain clinical features of CVID: asthma and allergic diseases
(39, 81), autoimmune manifestations (63, 65, 66), gastric cancer
(49), gastrointestinal manifestations (41, 76), granulomatous
manifestations (64, 78), or pulmonary manifestations (43, 45,
46, 69, 75).
Risk of Bias of Included Studies
Most included studies defined cases using the diagnostic criteria
of PAGID and ESID (27 studies); other used criteria were: the
ESID Registry working diagnosis criteria (8 studies),
International consensus document (3 studies), IUIS criteria
(2 studies), and WHO classification (4 studies). Seven studies
did not report which criteria were used but did describe a CVID
diagnosis that corresponded to the above approved
classifications. One study reported to use both the diagnostic
criteria of PAGID/ESID and the WHO classification (51). Lack
of routine B and T cell immunophenotyping in most studies
prohibited an accurate assessment of potential late-onset
combined immunodeficiency (LOCID). 37 studies (73%)
included all consecutive cases within the study period, with a
further 11 studies (22%) describing why a proportion of
potentially eligible cases were excluded. In the remaining 3
studies (6%), the proportion of consecutively included cases
was unclear.
A weakness of the included studies was lack of clarity at which
point in the diagnostic and follow-up pathway clinical features
were recorded. Twenty studies explicitly stated when clinical
manifestations occurred [at or before diagnosis (n=4), and both
at/or before diagnosis and during follow-up (n=16)]. The
remaining 31 studies were unclear as to when the reported
clinical manifestations occurred during the disease course.
Pooled Frequencies of Clinical
Characteristics From Meta-Analysis
Pooled frequencies of demographic information are shown in
Table 2. In pediatric CVID patients, males were in the majority
(62%, 95% CI 54-69), while females predominated in the adult
CVID patients (58%, 95% CI 53-64). The high pooled proportion
of consanguinity in the pediatric and total cohort should be





























Records excluded (n=1453) 
   1323 based on tle 
   130 based on abstract
Full-text arcles assessed for 
eligibility 
(n=151)
Full-text arcles excluded (n=96)
   6 had < 10 cases 
   7 had no primary data
   3 were inaccessible
   43 had insufficient detail on manifestaons









   21 added from snowball
   3 added at search update
Studies excluded (n=28)
   19 because of insufficient quality
   9 because of duplicate data
FIGURE 1 | Flow chart showing the study selection process.
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Median Mean Range Median Mean Range Median Mean Total
Adults
(38) USA 1998-2013 Hospital
records
1 34 – – – – – – – – – –
(39) USA 2008-2018 Hospital
records

































(37) Argentina 1997-2008 Hospital
records
1 10 41 – 18-69 – 9.5 – – – – –





1 104 – – – – – – – – – –
(42) Russia 1990-2011 Hospital
records





1 47 27 – – 9.5 – – 9.5 – – –
(44) France 2004-2007 French DEFI
database*
31 252 33.9 – – 6.9 – 0-55 – – – –
(5) USA 1986-2011 Hospital
records
1 473 – – – – – – – – 40 19.6%
(35) USA 1988-2016 USIDNET
registry*
– 264 – – 18-
76.9












1 134 – – – – – – – – – –
(46) USA 1985-2001 Hospital
records
1 69 – – – – – – – – – –
(47) Brazil 1980-2003 Hospital
records
1 71 – 30.9 – – 10.9 – 4.5 – 28.3 15.5%
(48) France – Hospital
records
1 57 – – – – – – – – – –
(36) USA 2005-2016 Hospital
records
1 107 – 45 – – – – – 5.7 – 4%
(49) Italy 2001-2017 Hospital
records
3 455 – 40.1 – – – – – 11.5 – 17.1%
Children
(50) Argentina – Hospital
records
1 28 11.2 11.1 4-16.1 – 5.4 – – – – –
(51) Taiwan 1990-2010 Hospital
records
1 10 – 4.5 – – 1.5 – – 9.8 – 0%
(40) USA 1988-2016 USIDNET
registry*
– 212 – – – – – – – – – –
(37) Argentina 1997-2008 Hospital
records
1 21 8.5 – 3-17 – 4.5 – – – – –
(52) Spain 1985-2005 Hospital
records
1 22 7.8 – 2.5-16 – – – – – 18 –
(53) Iran 1984-2010 Hospital
records
1 69 – 6.76 4-16 – 4.4 – – 5.2 21 21.7%
(Continued)
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Median Mean Range Median Mean Range Median Mean Total
(54) Poland 1995-2011 Hospital
records
1 49 8.8 – 2.4-
17.3
2.4 – 0-12.2 – – – –
(35) USA 1988-2016 USIDNET
registry*
– 193 – – 2-17 – – – – – – –















1 38 – 5.5 0.9-
12.7
– – – – – – –
(57) USA – Hospital
records
1 45 – – 2-16 – – – – – – –
(58) USA 1992-2005 Hospital
records
1 12 8 8.3 2-17 – – – – – – –
(59) Turkey 2003-2014 Hospital
records
1 28 5.9 6.7 1-15 – – – – – – –
(36) USA 2005-2016 Hospital
records
1 91 – 12 – – – – – 8.6 – 13%
All ages together
(60) Iran 1984-2013 Registry
database*
14 173 – 12.3 4-54 4 – 0.25-
39
– – 29 30%
(61) Turkey 2001-2008 Hospital
records
1 23 30.5 33 13-73 – – 1-32 – – – –
(62) Iran n/a-2014 Hospital
records
1 47 – 20.2 – – 9 – – 6.8 23 6%
(63) France 2004-2008 French DEFI
database*
– 311 35.2 – 16-58 – – – – – – –
(64) France – French DEFI
database*
– 436 – – – – – – – – – –
(26) Multiple 1996-2006 ESID registry# 7 334 33 35.3 – 5 7.5 0-61 22.5 25.6 – 14.5%
(65) USA n/a-2017 USIDNET
registry*
50 990 – – – – – – – – – –
(66) France 2013-2016 CEREDIH
registry*





1 32b 34.3 – 0-63 – – – 15.8 – – 2.9%






6 95 33 32 0.5-73 5 8.5 0.2-37 – – – 4%
(69) Spain – Hospital
records
1 19 – 23.2 – – – – – – – –
(70) Iran 1983-2013 Hospital
records
1 125 8.3 – 0-54 4 – 0-51 – – 25 27.2
(71) Turkey 2008-2014 Hospital
records
1 31 23 – – 14 – – – – – –
(72) Italy 1999-2005 Italian PID
Network*
26 224 – 26.6 2-73 – 8.9 – 11.5 11.5 34 6%
(73) Mexico – Hospital
records*
7 43 19 – – – 12.5 – – – – –
(74) Puerto Rico – Hospital
records





1 47 35 – 5-72 4 – 0.8-25 – – 12 17%
(76) Iran 1997-2004 Iranian PID
registry
1 39 12 16 3-55 – – – – – – –
(Continued)
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interpreted with caution (31% and 20% respectively; only one
study reported this for adults). This proportion varied
substantially per country. In an Argentinian cohort none had a
history of consanguinity (37), while the rate of consanguinity was
very high in an Iranian cohort (72%) (53).
In total, 147 out of a potential of 270 meta-analyses were
conducted. For the remaining 123 clinical manifestations, meta-
analysis was not possible since the features were each reported in
only one study. The high heterogeneity (I2) statistics in the meta-
analyses (mostly >80%) indicated that the degree of
heterogeneity between studies was greater than that expected
by chance alone and confirmed the appropriateness of random-
effects meta-analysis to generate pooled proportions.
There were 49 specific clinical manifestations for which it was
possible to calculate pooled proportions for the subgroup at
presentation, i.e. ‘at or before diagnosis’; these are shown in
Figure 2 in comparison with overall, i.e. ‘at, before or after’
diagnosis. The most frequent clinical manifestations at
presentation (reported in ≥39% of patients) are shown above
the grey dotted horizontal lines. A history of upper and/or lower
respiratory infections was present at diagnosis in three-quarters
of patients (upper respiratory tract infections in 73%, lower
respiratory tract infections in 73%, sinusitis in 59%,
pneumonia in 57%, bronchitis in 57% and otitis in 39%) and
severe bacterial infections in 8% (septicemia), 8% (mastoiditis),
6% (meningitis), and 4% (osteomyelitis).
Bronchiectasis was already present in almost one third of the
patients at or before the CVID diagnosis was made (28%, 95% CI
18-40). Non-infectious manifestations that were frequently
present at diagnosis were: lymphadenopathy (27%),
splenomegaly (13%), inflammatory bowel disease (11%), and
autoimmune hematological manifestations (autoimmune
cytopenia (10%) and idiopathic thrombocytopenia (6%)). The
pooled prevalences at presentation of urinary tract infection
(14%, 95% CI 5-25), thyroid disease (16%, 95% CI 0-43), and
diabetes mellitus (2%, 95% CI 0-7) correspond to the estimated












Median Mean Range Median Mean Range Median Mean Total
(77) USA 1973-1998 Hospital
records
1 248 – 31 3-79 – – – 7 – 25 27%
(78) USA – Hospital
records
2 455 26 – 2-59 – – – – – 25 20.5
(79) USA 2011-2015 Hospital
records
1 128 – – – – – – – – – –
(19) Italy 1985-2015 Hospital
records
1 75 40 – – 7 – – 9 10.24 30 5.3%
(6) Finland 2007-2015 Hospital
records$
3 106 – – – – – – – – – 9.4%
(80) Poland 1990-2017 Internet
database$
4 77 – 32.29 – – 10,13 – – 4.26 – –
(81) Iran – Hospital
records
1 187 – – – – – – – – – –
*Nationwide. #Continentwide. $Regionwide.
aThis is the mortality percentage of the total USIDNET cohort (n = 884).
bTwo patients with thymoma were excluded (Good syndrome).
CEREDIH, Centre de Référence Déficits Immunitaires Héréditaires; ESID, European society for immunodeficiency; FU, follow-up; GI, gastro-intestinal; Nr, number; PID, primary
immunodeficiency; pt, patients; USIDNET, United States Immunodeficiency Network.
TABLE 2 | Demographic parameters in adult-, pediatric-, and total cohorts.



















Males 305/526 62 (54-69) 62 571/1326 43 (37-48) 71 1819/3828 50 (47-54) 71
Females 221/526 38 (31-46) 62 755/1326 58 (53-64) 72 2009/3828 50 (46-53) 73
Family members
with PID
31/291 10 (6-15) 41 83/497 14 (9-20) 56 168/1283 12 (9-16) 66
Consanguinity 60/118 31 (0-87) 96 10 0a 238/769 20 (4-43) 97
PID, primary immunodeficiency disease.
aMeta-analysis could not be conducted because the feature was described in only one study.
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lifetime prevalence estimates in the general population of 30%
(82), 12% (83), and 0.9% (type 1) (84), respectively. An overview
of all reported clinical manifestations at and before diagnosis
with – when known – lifetime prevalence estimates from the
general population is included in Supplementary Table 4.
In Figure 3, all clinical manifestations that were present in
≥10% of patients are shown (as presented, whether or not likely
related to CVID); the CVID-associated manifestations are also
shown when present in <10% when they were considered
important to incorporate by the authors (based on obvious
relation with CVID in the current literature or consensus in the
field). We grouped these manifestations into eleven distinct
clinical categories according to the body system affected and the
clinical phenotypes described by Chapel et al. (26). An overview of
all reported clinical manifestations is included in Supplementary
Table 5. Many CVID patients developed non-infectious
manifestations during follow-up: bronchiectasis in 32%,
lymphadenopathy in 30%, splenomegaly in 29%, polyclonal
lymphocytic infiltration in 29%, and autoimmune manifestations
in 27%. In addition, a substantial number of patients developed
malignancies (10%) and atopic diseases during the entire disease
course [asthma (25%), allergic rhinitis (18%)].
Three quarters of the children (76%, 95% CI 57-91) developed
no other complications besides infections during the reported
follow-up periods (See Figure 4), while this percentage was
much lower in the adults (38%, 95% CI 27-49). Certain
infectious features of CVID, such as otitis, were more common
in children (55%, 95% CI 45-64) than in adults (32%, 95% CI 27-
37), whereas certain immune dysregulation features, such as
granulomatous-lymphocytic interstitial lung disease, chronic







Respiratory tract inf 86 (62-99) 92 (78-99)
Lower respiratory tract infc 73 (56-86) 78 (64-90)
Upper respiratory tract inf 73 (53-89) 84 (75-92)
Sinusitis 59 (47-71) 67 (57-77)
Pneumoniac 57 (43-69) 62 (54-70)
Bronchitis 57 (42-72) 62 (44-78)
Otitis 39 (28-49) 43 (35-51)
Allergic rhinitis 36 (9-68) 18 (8-31)
Asthma 31 (3-69) 25 (17-35)
Gastrointestinal tract inf 29 (15-44) 29 (21-38)
Bronchiectasis 28 (18-40) 32 (26-38)
Lymphadenopathy 27 (0-90) 30 (20-42)
Chronic diarrhoea 21 (11-34) 27 (21-34)
Autoimmunity 19 (11-28) 27 (22-32)
Allergy 16 (0-63) 33 (13-56)
Thyroid disease (all)d 16 (0-43) 9 (4-16)
Conjuncvis 14 (6-25) 10 (5-16)
Urinary tract infectiond 14 (5-25) 14 (11-18)
Splenomegaly 13 (5-23) 29 (22-37)
Sjogren’s syndrome 13 (2-25) 3 (1-6) 
Atopic dermatitis 12 (4-24) 12 (7-18)
IBD 11 (3-23) 10 (6-16)
Autoimmune cytopenia 10 (7-14) 13 (10-17)
Skin infections 10 (6-15) 13 (10-17)
Oral/dental infections 10 (3-21) 4 (3-6) 
Bloodstream infection 8 (4-13) 9 (5-13)
Mastoidis 8 (3-16) 3 (1-7) 
Growth retardation 8 (1-22) 13 (7-22)
ITP 6 (4-9) 10 (7-14)
Seronegave arthris 6 (2-12) 4 (2-7) 
Unexplained granuloma 5 (4-7) 12 (9-16)
Infectious meningitis 5 (3-9) 7 (5-9) 
Osteomyelis 4 (1-9) 4 (1-8) 
Malignancy 4 (1-8) 10 (7-14)
Rheumatoid arthris 4 (1-10) 3 (2-4) 
AIHA 3 (2-5) 6 (4-8) 
Peritonis 3 (1-8) 4 (1-8) 
Autoimmune thyroidis 3 (0-8) 4 (2-6) 
Autoimmune neutropenia 3 (0-9) 4 (2-6) 
Cutaneous abscesses 3 (1-6) 5 (2-10)
Oral candidiasis 3 (1-5) 6 (2-11)
Splenectomy 3 (1-6) 6 (3-8) 
Vitiligo 2 (1-5) 5 (3-8) 
Septic arthris 2 (1-4) 4 (1-8) 
Diabetes mellitusd 2 (0-7) 2 (1-3) 
SLE 2 (0-6) 1 (1-2) 
Lymphoid malignancy 2 (0-4) 5 (3-7) 
Celiac disease 1 (0-4) 3 (2-4) 
0 10 20 30 40 50 60 70 80 90 100 0 10 20 30 40 50 60 70 80 90 100
FIGURE 2 | Frequency of reported clinical manifestations at presentation vs overall clinical manifestations during the disease course.The most frequent clinical
manifestations at presentation (reported in ≥39% of patients) are shown above the grey dotted horizontal lines. aNumber of patients ranged from 44 to 1137; number
of studies ranged from 2-15. bNumber of patients ranged from 51 to 4061; number of studies ranged from 2-31. cPneumonia and lower respiratory tract infections
were not combined into one category, as they were often mentioned as two separate categories in the included studies. dThe prevalence of this clinical manifestation
is similar or lower to lifetime prevalence estimates in general population. IBD, inflammatory bowel disease; inf, infections; ITP, idiopathic thrombocytopenic purpura;
AIHA, autoimmune hemolytic anemia; SLE, systemic lupus erythematosus.
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diarrhea and inflammatory bowel disease were more prominent
in adults (33%, 95% CI 13-57; 34%, 95% CI 22-48; 18%, 95% CI
6-33; respectively) than in children (6%, 95% CI 4-9; 17%,
95% CI 11-24; 3%, 95% CI 1-6, respectively). Bronchiectasis
were more common in adults (36%, 95% CI 27-46) than in
children (16%, 95% CI 9-25). An overview of all reported
clinical manifestations in children and adults is included in
Supplementary Table 6.









Clinical phenotypea     
Infections only 1677 (16) 48 (39-58) 93 
 
PLI 2252 (9) 29 (22-37) 92 
Autoimmunity 4061 (28) 27 (22-32) 91 
Malignancyb 3389 (20) 10 (7-14) 87 
Enteropathy 2400 (10) 9 (6-13) 86 
Lymphoid malignancy 3392 (20) 5 (3-7) 81 
    
Respiratory involvement     
Respiratory tract infections 543 (5) 92 (78-99) 93 
 
Upper RTI 794 (15) 84 (75-92) 89 
Lower RTI 270 (8) 78 (64-90) 84 
Sinusitis 1887 (21) 67 (57-77) 95 
Pneumoniac 1876 (22) 62 (54-70) 92 
Bronchitis 1166 (8) 62 (44-78) 97 
Chronic lung disease 716 (3) 44 (27-63) 93 
Otitis 1444 (18) 43 (35-51) 86 
COPD 51 (2) 34 (14-58) 61 
Allergy 419 (6) 33 (13-56) 94 
Bronchiectasis 3720 (31) 32 (26-38) 93 
Asthma 1819 (15) 25 (17-35) 94 
Allergic rhinitis 1282 (7) 18 (8-31) 95 
Pharyngis/tonsillitis 575 (3) 18 (12-24) 68 
GLILD 2094 (11) 15 (7-25) 96 
ILD 629 (4) 13 (6-23) 88 
Idiopathic lung fibrosis 247 (6) 12 (1-30) 92 
Lymphoid hyperplasia 1667 (11) 10 (5-17) 91 
Conjuncvis 872 (6) 10 (5-16) 87 
    
Gastrointesnal involvement     
Increased IEL 53 (1) 60 n/a 
 
Gastrointestinal tract infectiond 1566 (14) 29 (21-38) 92 
Gastris 286 (3) 28 (22-35) 17 
Chronic diarrhoea 1885 (14) 27 (21-34) 88 
Gastric metaplasia 53 (1) 25  n/a 
Food intolerance 32 (1) 19 n/a 
GERDb 565 (3) 16 (6-25) 84 
Malabsorpon 1099 (5) 13 (4-26) 96 
Villous atrophy 291 (2) 11 (1-28) 83 
Inflammatory bowel disease 1940 (14) 10 (6-16) 90 
Helicobacter pylori 620 (4) 9 (3-18) 82 
Lymphocyc colitis 92 (2) 9 (4-16) 0 
Atrophic gastris 652 (7) 5 (3-9) 62 
Celiac disease 1586 (9) 3 (2-4) 25 
Gastric cancer 1754 (11) 2 (1-4) 61 
    
Hepac involvement     
Unexplained hepatomegaly 1507 (8) 14 (8-22) 93 
     
Urinary tract involvement     
Urinary tract infectionb 1267 (12) 14 (11-18) 66 
Pyelonephris 205 (2) 8 (0-22) 77 
    
Hematologic involvement     
Autoimmune cytopenia 3131 (17) 13 (10-17) 86 
 
Unknown/other anaemia 988 (1) 10 n/a 
Iron deficiency anaemiab 1322 (2) 10 (2-22) 97 
ITP 2717 (18) 10 (7-14) 84 
Bloodstream infection 1872 (16) 9 (5-13) 85 
AIHA 2895 (20) 6 (4-8) 77 
Autoimmune neutropenia 1944 (9) 4 (2-6) 68 
Pernicious anaemia 2142 (10) 3 (1-5) 84 
    
Neurologic involvement     
Headaches/migraineb 457 (1) 17 n/a 
 
Infectious meningitis 1672 (17) 7 (5-9) 62 
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FIGURE 3 | Continued
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DISCUSSION
To our knowledge, our study is the first systematic review and
meta-analysis of pooled clinical manifestations in patients with
CVID. Our findings can help clinicians to recognize CVID, and
to estimate how common a clinical manifestation is in pediatric
and adult CVID. We identified 134 different presenting clinical
manifestations in patients diagnosed with CVID (the limited
number of data impeded splitting up between children and
adults). In addition, we identified 270 different clinical
manifestations occurring during the entire course of the
disease (147 in children and 170 in adults). Most frequent
presenting manifestations were recurrent upper respiratory
tract infections (73%), lower respiratory tract infections (73%),
sinusitis (59%), pneumonia (57%), bronchitis (57%) and otitis
(39%), concurrent with the first two ESID and first three JMF
warning signs for PID (20, 21). However, these manifestations
are also frequent in the general population and may lack
discriminating value, unless their unusually recurrent and
persistent nature is recognized (85). Other alerts to potential
PID that are in line with the JMF warning signs that may be more
discriminatory include severe bacterial infections (osteomyelitis
in 4%, meningitis in 6%, septicemia in 8%, mastoiditis in 8%),
which are clearly more frequent than lifetime prevalence in the
general population. Recent studies already demonstrated a high
incidence of antibody deficiency in patients with pneumococcal
meningitis (86–88), confirming our finding of a high frequency
of infectious meningitis in CVID, but we also show a high
incidence of bloodstream infections, mastoiditis and to a
somewhat lesser extent osteomyelitis in CVID patients. This
suggests that the incidence of CVID may also be increased in
patients with bloodstream infections, mastoiditis and
osteomyelitis without other clear predispositions and suggest
screening for CVID could be useful in these patients. This
finding warrants further exploration.
One of the most reliable alerts to potential CVID was CVID in
the family (12% of the total reviewed population). Both the six ESID
and ten JMF warning signs make no mention of other presenting
manifestations than frequent and/or severe infections, such as
bronchiectasis (28%), lymphadenopathy (27%), splenomegaly
(13%), chronic diarrhea (21%), inflammatory bowel disease
(11%), or autoimmune hematological manifestations
(autoimmune cytopenia (10%) and idiopathic thrombocytopenia
(6%)). Our results suggest that also lymphoproliferative,
Bone and joint involvement 
Arthralgia 457 (1) 20 n/a 
Osteoporosis/osteopeniab 480 (2) 10 (1-25) 92
Septic arthris 719 (7) 4 (1-8) 72
Osteomyelis 807 (6) 4 (1-8) 83
Rheumatoid arthris 1922 (8) 3 (2-4) 42
Mastoidis 532 (3) 3 (1-7) 64
Lymph node and spleen involvement
Lymphadenopathy 2122 (13) 30 (20-42) 96
Splenomegaly 3153 (22) 29 (22-37) 94
Non-malignant lymphoproliferaon 1462 (6) 28 (16-40) 94
Non-Hodgkin’s lymphoma 2698 (13) 4 (3-5) 56
Leukaemiab 1581 (4) 1 (1-2) 22
Muco/cutaneous involvement 
Neutrophilic dermatitis 31 (1) 23 n/a 
Clubbing  138 (2) 19 (0-73) 97
Aphthous lesions 147 (3) 16 (5-31) 77
Skin infections 1033 (11) 13 (10-17) 59
Atopic dermatitis 1307 (6) 12 (7-18) 86
Cutaneous abscesses 72 (6) 5 (2-10) 79
Vitiligo 2440 (12) 5 (3-8) 81
Alopecia 1425 (6) 3 (2-4) 0 
Other clinical manifestaons
Fague 457 (1) 39 n/a 
Growth retardation/weight loss 759 (8) 13 (7-22) 87
Unexplained granulomae 2348 (11) 12 (9-16) 79
0 10 20 30 40 50 60 70 80 90 100
FIGURE 3 | Frequency of reported clinical manifestations of patients with common variable immunodeficiency. All clinical manifestations that were present in ≥10%
of patients are shown; the CVID-associated manifestations are also shown when present in <10% when they were considered important to incorporate by the
authors (based on current literature and consensus in the field). aDerived from Chapel et al. (26). bThe prevalence of this clinical manifestation is similar or lower to
lifetime prevalence estimates in general population. cStreptococcus pneumoniae 15%, 95% CI 8-23; Hemophilus influenzae 19%, 95% CI 8-33; Moraxella catarrhalis
7%, 95% CI 0-19; Staphylococcus aureus 7%, 95% CI 3-12; Mycobacterial infection 1%, 95% CI 0-2; Pneumocystis jiroveci 1%, 95% CI 0-2%; Pseudomonas 6%,
95% CI 2-10; Aspergillus 3%, 95% CI 1-5; Mycoplasma 2%, 95% CI 0-4. dGiardia intestinalis 13%, 95% CI 7-21; Candida species 10%, 95% CI 4-19; Salmonella
species 6%, 95% CI 2-12; Campylobacter species 4%, 95% CI 1-8.eIntestinal granulomatosis 1%, 95% CI 0-4; liver granuloma 3%, 95% CI 1-6; granuloma in
lymph node 2%, 95% CI 0-5; granuloma in spleen 1%, 95% CI 0-2; skin granuloma 1%, 95% CI 0-2. AIHA, autoimmune hemolytic anemia; COPD, chronic
obstructive pulmonary disease; CVID, common variable immunodeficiency disorders; GERD, gastro-esophageal reflux disease; GLILD, granulomatous and
lymphocytic interstitial lung disease; IEL, increased intraepithelial lymphocytes; ILD, interstitial lung disease; ITP, idiopathic thrombocytopenic purpura; PLI, polyclonal
lymphocytic infiltration; RTI, respiratory tract infection.
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% (95% CI) 
Pooled
proporon, 
% (95% CI) 
Clinical phenotype
Infections only 76 (57-91) 38 (27-49)
Autoimmunity 14 (5-27) 21 (12-30)
Enteropathy 10 (3-20) 14 (10-18)
Lymphoid malignancy 5 (2-10) 6 (5-8) 
Malignancy 5 (3-7) 16 (11-21)
Respiratory involvement 
Otitis 55 (45-64) 32 (27-37)
Sinusitis 62 (50-74) 74 (60-86)
Upper respiratory tract inf 69 (45-89) 79 (66-90)
Pneumonia 61 (50-71) 66 (51-79)
Bronchitis 59 (11-71) 72 (38-97)
Bronchiectasis 16 (9-25) 36 (27-46)
GLILD 6 (4-9) 33 (13-57)
Lymphoid hyperplasia 2 (0-6) 11 (2-24)
Asthma 3 (5-9) 33 (21-47)
Intersal lung disease 6 (1-14) 15 (3-35)
Gastrointesnal involvement 
Chronic diarrhoea 17 (11-24) 34 (22-48)
Gastrointestinal tract inf 35 (18-55) 34 (8-65)
IBD 3 (1-6) 18 (6-33)
Celiac disease 3 (1-5) 2 (1-4) 
Malabsorpon 5 (3-8) 11 (0-32)
Hepac involvement 
Autoimmune hepas 2 (0-6) 4 (0-12)
Urinary tract involvement 
Urinary tract infection 11 (8-15) 15 (12-19)
Hematologic involvement 
ITP 9 (2-21) 6 (2-12)
Autoimmune cytopenia 15 (4-30) 16 (7-27)
AIHA 6 (4-9) 5 (2-8) 
Autoimmune neutropenia 4 (0-11) 2 (0-6) 
Pernicious anemia 1 (0-3) 1 (1-3) 
Bloodstream infection 8 (5-12) 12 (9-16)
Neurologic involvement 
Infectious meningitis 7 (2-13) 7 (4-9) 
Lymph node and spleen involvement
Splenomegaly 20 (6-39) 30 (16-46)
Non-hodgkin’s lymphoma 1 (0-3) 5 (4-6) 
Hodgkin’s lymphoma 5 (2-11) 1 (0-2) 
Endocrinological involvement 
Thyroid disease 8 (0-24) 29 (12-50)
Autoimmune thyroidis 3 (1-6) 6 (2-12)
Diabetes mellitus 2 (0-4) 4 (0-14)
Muco/cutaneous involvement
Psoriasis 1 (0-6) 4 (2-7) 
Vitiligo 2 (1-4) 2 (1-4) 
Warts 6 (3-9) 5 (3-7) 
Skin cancer 1 (0-3) 5 (2-8) 
Skin infections 16 (9-25) 13 (6-23)
Recurrent HZ infections 19 (12-27) 7 (2-15)
Oral candidiasis 12 (8-16) 6 (0-20)
Other clinical manifestaons
Unexplained granuloma 6 (2-12) 15 (7-25)
Vasculitis 1 (0-5) 2 (2-4) 
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FIGURE 4 | Frequency of reported clinical manifestations in children vs adults. IBD, inflammatory bowel disease; inf, infections; GLILD, granulomatous and
lymphocytic interstitial lung disease; ITP, idiopathic thrombocytopenic purpura; AIHA, autoimmune hemolytic anemia.
Janssen et al. CVID Clinical Presentation Data: Meta-Analysis
Frontiers in Immunology | www.frontiersin.org March 2021 | Volume 12 | Article 62070911
gastrointestinal and autoimmune manifestations should be
included in warning signs for predicting PID. This is important,
because we still fail to detect the disease early enough. Increasing
awareness of this varied and complex presentation of CVID can
lead to earlier detection and initiation of treatment.
Our findings show a male predominance in children with
CVID (62%), but a female predominance in adults (58%). This is
also observed in atopic disease and we previously described this
in patients with unclassified primary antibody deficiency (89),
but it has not previously been recognized in CVID. This sex shift
may indicate that etiology differs in different age groups. Early
childhood male predominance suggests X-linked heredity is
present in some boys diagnosed with the disease; adult female
predominance suggests sex hormone effects, environmental
exposure, and epigenetic influences may play a role (90). This
implicates that future studies that attempt to define mechanisms
that underpin CVID should be stratified according to sex.
There were clear differences in clinical manifestations
occurring during the disease course between children and
adults with CVID. Overall prevalence of bronchiectasis was
36% in adults vs 16% in children. Persistence of an ‘infection-
only’ phenotype was much more prevalent in pediatric than in
adult CVID (76 vs 38%). During childhood, three quarters of
patients developed no other complications besides infections,
while this percentage was much lower during follow up in adults
(38%). Immune-dysregulation features, such as granulomatous-
lymphocytic interstitial lung disease (15 vs 6%), chronic diarrhea
(34 vs 17%), and inflammatory bowel disease (18 vs 3%) were
more prominent in adults compared to children. A possible
explanation could be longer ongoing inflammation and longer
follow-up in the adults (43). One is an adult for many more years
than one is a child, thus there are many more physician visits in
the adult years and more opportunities for CVID complications
to be observed. The different signs and symptoms observed in
CVID between pediatric and adult age, with more non-infectious
disease complications in adults, suggest that different monitoring
strategies for children and adults during follow-up may
be warranted.
Most common non-infectious manifestations included
bronchiectasis (32%), lymphadenopathy (30%), splenomegaly
(29%), polyclonal lymphocytic infiltration (29%), and
autoimmune manifestations (27%). While only a quarter of
CVID patients had features of immune dysregulation at
presentation, this increased to about half of the patients
throughout the course of the disease. This suggests that these
manifestations more often occur later in the disease course. It is
crucial that CVID patients are monitored for the development of
these complications, because some of these are difficult to treat
and associated with increased mortality (4,14). The coincidence of
immunodeficiency and immune dysregulation can be explained
by several mechanisms. Immunodeficiency may result in
insufficient clearance of microbial antigens, and the resulting
persistent antigenic exposure could then trigger granulomatous
disease and autoimmunity (91). Both complications have been
linked to hyperplastic germinal centers enriched with polyclonal/
self-reactive B-cell clones (92), and immature B cell development
(25) in CVID. In addition, low numbers of regulatory T-cells (91,
93), and an increasing number of genetic defects (94) have been
associated with immune dysregulation in CVID. Additional
factors, such as commensal microbial dysbiosis and epigenetic
modifications remain to be better elucidated (95).
Interestingly, we found high pooled prevalences of atopic
diseases both at presentation of CVID and during the entire
disease course (asthma 31 vs 25%, allergic rhinitis 36 vs 18%).
The pooled prevalences of asthma and allergic rhinitis are higher
in CVID compared to the estimated lifetime prevalences in the
general population of 13.6% (96) and 6.6% (97), respectively.
This should be interpreted with caution because of the
considerable heterogeneity between the studies (I2 >80). Also,
not all patients underwent cutaneous or in vitro testing or
spirometry to support these diagnoses, nor was it reported how
often the asthma was atopic in nature. It is possible that
symptoms derived from the deficient immune system were
interpreted as atopic disease, on the other hand, atopic
disorders could actually be more prevalent in CVID. Overlap
between the symptoms of atopic diseases and immunodeficiency
may lead to delayed diagnosis, so it is important to consider
CVID in patients with atopic diagnoses who are insufficiently
responsive to standard treatment and who also have infections.
To further elucidate the association between atopic diseases and
CVID, a prospective multi-center study in a large unselected
CVID cohort would be needed.
A substantial number of patients developed malignancies
during the disease course (10%, 95% CI 7-14). This pooled
prevalence is comparable with the result of a previous focused
meta-analysis of malignancy prevalence in CVID (8.6%, 95% CI
7.1-10) (98). Also, in alignment with previous reports the most
common malignancies were lymphoid malignancies (5%, 95% CI
3-7) and gastric cancers (2%, 95% CI 1-4) (49, 72, 98–100). The
lack of data on controls impedes comparison of our results to the
normative population, but the prevalences are higher compared
to the lifetime prevalence estimates in the United States
population (lymphoid malignancies 2.3%, gastric cancers 0.8%)
(101). The prevalence of cases with lung-, colorectal-, uterine-,
liver-, and pancreatic cancer and leukemia were similar to what
one might expect in the general population according to the
lifetime risk statistics based on the United States population
(Supplementary Table 4) (101).
Strengths and Limitations
This analysis collates data from >8000 patients (850 children,
2998 adults, 4673 not specified/both) in 51 studies from 18
different countries. The included studies were conducted in
Europe, North- and South America, and Asia; there were no
studies from Australia or Africa. Our review adhered to rigorous
methods, including a systematic search strategy, and explicit
inclusion criteria (102). The findings therefore present the most
comprehensive and internationally relevant presenting
manifestations for clinicians worldwide.
The study has some limitations and potential sources of bias.
The main limitations reflect deficits in the design and reporting of
the included studies. Accuracy of our systematic analysis depends
on the quality of the published and supplementary data that we
included. All studies provided data on cases only, and not on
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controls. Therefore, we were unable to compare the frequency of
clinical manifestations in CVID patients to the frequency in the
general population. Publication bias could have led to
overrepresentation of more complex cases of CVID, and
therefore higher incidences of non-infectious complications. We
did not include unpublished data. Heterogeneity between included
studies was high. Most included studies provided little motivation
for the selection of the clinical manifestations studied, thus it is
difficult to account with certainty for the variation in number and
choice of the selected clinical manifestations. The variation in
reported clinical phenotypes and complications between cohorts
may stem from differences in study populations (for instance, due
to access to health care, rate at which patients are properly
diagnosed, degree of consanguinity, or population genetic
differences), use of different methods to diagnose findings,
underreporting of histological diagnoses because biopsies are not
performed, and the use of different definitions for CVID. Full
consensus regarding the definition of CVID does not yet exist
(103). Also, in a few series, a small proportion of pediatric and
adult patients had opportunistic infections and/or a low CD4 T-
cell count, and those patients should actually be classified as a
combined immunodeficiency. This phenotype has been re-named
in adults as late onset combined immunodeficiency (LOCID) by
the IUIS. In addition, given the rapid progress in next-generation
sequencing, in non-consanguineous populations, a causative
mutation may currently be identified in ~25% of CVID patients
(104). Ideally, patients with monogenic diseases and LOCID
should have been excluded from our analysis, but it was not
possible to identify them exactly in the described cohorts (105).
Transient hypogammaglobulinemia of infancy may have been
misdiagnosed as CVID in some of the children included in the
different series. As we only included children diagnosed at age >4
years it is unlikely this accounts for a large percentage of
included children.
Implications for Future Research
Our study identified two key limitations in the current evidence
base on CVID presentation. First, we found relatively few studies
that explicitly reported data on clinical signs and symptoms at or
before diagnosis of the disease. We lack data on the frequency
and time of onset of symptoms from the first symptoms at home
to the final diagnosis. Second, only few studies compared
pediatric with adult CVID. Further large, multicenter,
prospective cohort studies, separately describing children and
adults, would address these gaps.
CONCLUSIONS
In conclusion, this meta-analysis confirms the high frequency of
upper and/or lower respiratory tract infections in CVID at
presentation, but also shows a remarkably high incidence of
severe bacterial infections (osteomyelitis in 4%, meningitis in 6%,
septicemia in 8%, mastoiditis in 8%) compared to lifetime
prevalence in the general population. This suggests that the
incidence of CVID may also be high in patients with severe
bacterial infections without other clear predispositions and
suggests screening for CVID might be useful in these patients.
These findings warrant further exploration. In addition, CVID
patients commonly present with other manifestations than
frequent or severe infections – which are not included in ESID
and JMF warning signs for identifying patients with primary
immunodeficiencies. Not only the infectious, but also the
immune dysregulation features (shown in Figure 2), should
alert to the possibility of CVID, regardless whether they occur
with or without recurrent infections. The bimodal sex
distribution in patients with CVID implicates that future
studies that attempt to define mechanisms that underpin
CVID should be stratified according to sex.
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